Australia's largest stock trading and investment forum Australia's #1 stock forum

CDY

Click for more information

1.43%

7.1¢ cellmid limited

Don’t waste your time seeking any more responses from me,...

First 18 Last

Share
Profile

Follow
Taurean7

1,334 Posts.

1004

21/02/19

13:49

Post #: 37516451
Share

Originally posted by phillit ↑

Originally posted by Taurean7
There is an obvious lack of understanding of the nature of IP licensing.

A biotech company (here Cellmid) does not engage a partner to carry out research on its behalf on the possible application of its IP towards a diagnostic or therapeutic application.

The partner company pays a contracted initial milestone amount to access the IP for it’s own investigation into a possible application of its own choice. Once it makes that payment it is no longer any of Cellmid’s business how that company chooses to plan and undertake its study. That includes giving any form of a report on progress or on results obtained.

If the partner has reached the point in development that it believes it has a product now ready for commercialisation it normally would need to then contact Cellmid to activate a secondary milestone payment as defined by the contract, allowing it to go forward. That should be the first time that Cellmid formally hears again from the partner. Successful commercialisation normally would involve later royalty payments.

There are many possible reasons for delays, including internal corporate politics and research personnel career changes. There has been some indication that internal politics due to corporate restructuring may apply to the Quest/Celera contract.

There would be no benefit to the partner to have the results of its investigations revealed to anyone prior to being commercialisation ready. If progressing well this might encourage a competitor to commence a similar investigation. If not progressing well for whatever reason, why not let a potential competitor expend the same time and monetary costs to find that out for themselves?

For these reasons it would even be inappropriate for Cellmid to request some indication of progress achieved. Put simply, it is none of Cellmid’s business. There likely would be some form of confidential personal interactions as a matter of courtesy.

Claiming that management is intentionally silent or lax in not reporting on progress simply indicates once again ignorance of the nature of the business. Yet another example of unjustified negativity.

Originally posted by Taurean7
Phillit

I have no familiarity with the specific arrangements existing between Cellmid and its licensing partners other than has been released in the relevant ASX announcements or available through passing reference in its various reports. For budding detectives, some clues are available through the ‘licence fees and royalties’ item of financial reports.

I am familiar with the many sources of complexity in IP management and the requirement for confidentiality by both a company and its licensing partner.

Any technical progress or results obtained by a partner become part of its own IP, and there can be no advantage in releasing it, even to the licensing company, unless it has become patent protected. Even indicating whether a program is currently active provides information to a potential competitor.

Cellmid is in a position to provide general updates to shareholders on progress achieved its own product development programs because of the wide patent protection that it holds on the midkine technology.

Originally posted by tsuba
I think it needs to be accepted that there are people contributing to this forum who have actual first hand knowledge and experience in the areas that they go to great lengths in explaining to others who have no knowledge in those areas including me.T7 is extremely good at writing concise and easy to understand pros and a credit to him for that too.
Too late. Already admission no knowledge, just guesswork by the poster you are defending.

Expand

Don’t waste your time seeking any more responses from me, Phillit. I have no intention of providing further support for your struggle with cognitive ability.

CDY Price at posting: 24.0¢ Sentiment: Buy Disclosure: Held
8 Upvote

6 Great analysis

Reply

Top Stories

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

ADD

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

HotCopper Highlights: Your most watched stocks for Week 48, 2024

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

RSG

Resolute shares bounce back as second payment made to Mali government to secure workers' release

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

First 18 Last

Add CDY (ASX) to my watchlist